Search Results

A strong agonist, fails to reduce binding of a labeled NAM—not because of irreversibility, but because The takeaway:  what looks like pharmacology failure may be a systems problem .

A GPCR program can have world-class science, top-tier talent, and millions in funding — and still fail A few familiar failure points: Fragmented Data: GPCR programs spew data across files, folders, and inboxes

latest lecture delivers a paradigm shift for pharmacologists working on drugs where in vitro potency fails

This opens up a new pharmacological space—and a reason to revisit “failed” targets with fresh eyes. access transforms the kinetic profile of your drug, which may be the difference between success and failure

Inefficient structure-activity relationship (SAR) cycles Wasted optimization efforts Focus on leads that fail

This is a chance to shape the next scientific consensus on how GPCRs work, signal, and fail.

Solve the in vitro/in vivo disconnect:  Understand why traditional potency measurements often fail to Discover how to identify and target cryptic intracellular allosteric sites, opening up new avenues for "failed

Alex Serafini  explains, this conventional bottom-up approach often fails to deliver therapies that truly Why This Approach Matters In pain research, bottom-up approaches often fail to translate.

of RGS proteins — particularly RGS4  — in modulating pain circuits in ways that traditional targets fail

Teams chase the wrong assays, too late to pivot Milestones slip—and nobody realizes until it’s too late Failing science stalls without operational structure ✅ Scattered data = missed insights = wasted time ✅ You can’t fail

In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives

You'll learn why some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge

And yes, you'll even meet the man who turned failed experiments into a Nobel Prize-winning discovery

Here’s the surprising truth: up to 80% of GPCR-targeted drugs fail—not because of poor chemistry, but

Moment: Try the Crazy Idea When a collaborator offered a neuroma model (one where opioids usually fail

“We’ve seen these modulators rescue opioid function where it completely fails in neuroma models.

Collaboration Targeting Neurological Diseases Achieves First R&D Milestone Tectonic bets on GPCR heart failure

Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval Tectonic bets on GPCR heart failure

on their work entitled β-arrestins and their potential role in heart failure. Dr. inflammatory diseases β-adrenergic receptor signaling mediated by β-arrestins and its potential role in heart failure

Different reviews have extensively described the success and failure in drug discovery on chemokine receptors

development of databases supporting medical research ‘Define your own success’: Duke leaders talk success, failure

GPCRs in Oncology and Immunology A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure

and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure

Immunology and Oncology The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure

GPCRs in Cardiology, Endocrinology, and Taste Targeting G Protein-Coupled Receptors for Heart Failure

autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure

Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure

autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure

Treatment of cells with YM failed to inhibit signaling by these PM-restricted αqQ209L.

β-arrestin2 play multiple roles in the pathological mechanisms of a wide range of diseases including heart failure